Please assess the completion status of the following clinical trial:

Trial Title: Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a pathologically documented unresectable or metastatic solid malignant tumor, with HER2 expression \[immunohistochemistry (IHC) 3+, 2+, or 1+ and/or in situ hybridization (ISH) +\], Next Generation Sequencing, or other analysis techniques as appropriate\] that is refractory to or intolerable with at least one prior systemic chemotherapy regimen, or for which no standard treatment is available~* Has a left ventricular ejection fraction (LVEF) ≥ 50%~* Has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1~Exclusion Criteria:~* Has a contraindication for receiving ritonavir or itraconazole according to the prescribing information~* Has a medical history of myocardial infarction within 6 months before enrollment or symptomatic congestive heart failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: DS-8201a + Ritonavir (Type: EXPERIMENTAL): DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
- Cohort 2: DS-8201a + Itraconazole (Type: EXPERIMENTAL): DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3

Based on this trial design, predict the completion outcome and termination type (if applicable).